Drug Trial Radar · NCT04798430
Long-term Efficacy and Safety of OLE LIB003 in HoFH, HeFH, and High-risk CVD Patients Requiring Further LDL-C Reduction
Last checked: Nov 20, 2026Latest source record: Oct 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
2,000
Planned (sponsor's estimate)
Start
Dec 3, 2020
Primary completion
Jul 30, 2025
Study completion Dec 31, 2025
Sponsor
- Lead sponsor
- LIB Therapeutics LLCIndustry
- Sponsor type
- Industry
- Collaborators
- Medpace, Inc.
- First posted
- Mar 15, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 10 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The study is to assess the long-term safety, tolerability, and efficacy after 48 and 72 weeks with monthly (Q4W \[\<31 days\]) dosing of subcutaneous (SC) LIB003 300 mg administered in patients with CVD or at high risk for CVD (including HoFH and HeFH) on stable diet and oral LDL-C lowering drug therapy who completed one of the LIB003 Phase 3 base studies.
Conditions
- Cardiovascular Disease With Mention of Arteriosclerosis
- Elevated Cholesterol
- Familial Hypercholesterolemia
Interventions
lerodalcibepDrug
PCSK9 inhibitor
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of Treatment-Emergent Adverse Events as assessed by Medical Dictionary for Regulatory Activities as severe, moderate or mild after 48 and 72 weeksTime frame: 72 weeks
Locations
12 sites in 6 countries. Site status is shown where the registry gives one.
NorthShore University Health System
Evanston, Illinois
Sterling Research Group
Cincinnati, Ohio
The Lindner Research Center
Cincinnati, Ohio
Metabolic & Atherosclerosis Research Center (MARC)
Cincinnati, Ohio
G.B. Pant Institute of Postgraduate Medical Education & Research
New Delhi, India
Department of Medicine, Hadassah University Hospital
Jerusalem, Israel
Rabin Medical Center, Beilinson Hospital,
Petah Tikva, Israel
Lipid Clinic, Oslo University Hospital
Oslo, Norway
Carbohydrate and Lipid Metabolism Research Unit
Johannesburg, Gauteng, South Africa
Division of Lipidology, Department of Medicine University of Cape Town
Cape Town, Western Province, South Africa
Afyonkarahisar Health Sciences University
Afyonkarahisar, Turkey (Türkiye)
Ege University Medical School
Izmir, Bornova, Turkey (Türkiye)
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.